Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.

European journal of clinical pharmacology - 1 May 2004

Jetter Alexander, Kinzig-Schippers Martina, Skott Andreas, Lazar Andreas, Tomalik-Scharte Dorota, Kirchheiner Julia, Walchner-Bonjean Monika, Hering Ursula, Jakob Verena, Rodamer Michael, Jabrane Wafaâ, Kasel Dirk, Brockmöller Jürgen, Fuhr Uwe, Sörgel Fritz

Abstract excerpt

OBJECTIVES: The hypoglycaemic drug tolbutamide is used for assessment of CYP2C9 activity in vivo. However, therapeutically active doses of 500 mg bear the risk of hypoglycaemia, and a tolbutamide-derived parameter based on a single plasma or urine concentration reflecting CYP2C9 activity accurately is lacking. METHODS: We examined tolbutamide and its metabolites 4'-hydroxy-tolbutamide and carboxytolbutamide in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, Liquid

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP2C9

Share to Mass Spectrometry

Share to Metabolic Clearance Rate

Share to Pilot Projects

Source

Identifiers

PMID: 15045499
DOI: 10.1007/s00228-004-0754-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.PMID 15045499Read ↗

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.Semantic proximity Read ↗

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.Semantic proximity Read ↗

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.Semantic proximity Read ↗

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Semantic proximity Read ↗

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.Semantic proximity Read ↗

Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide.Semantic proximity Read ↗

CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.Semantic proximity Read ↗

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.Semantic proximity Read ↗

[Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].Semantic proximity Read ↗

In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.Semantic proximity Read ↗

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.Semantic proximity Read ↗

Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.